Cargando…

The Role of the Microbiome-Brain-Gut Axis in the Pathogenesis of Depressive Disorder

The role of gut microbiota and its association with the central nervous system via the microbiome-brain-gut axis has been widely discussed in the literature. The aim of this review is to investigate the impact of gut microbiota on the development of depression and underlying molecular mechanisms. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Młynarska, Ewelina, Gadzinowska, Joanna, Tokarek, Julita, Forycka, Joanna, Szuman, Aleksandra, Franczyk, Beata, Rysz, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105444/ https://www.ncbi.nlm.nih.gov/pubmed/35565888 http://dx.doi.org/10.3390/nu14091921

Ejemplares similares

What Is the Role of Gut Microbiota in Obesity Prevalence? A Few Words about Gut Microbiota and Its Association with Obesity and Related Diseases
por: Tokarek, Julita, et al.
Publicado: (2021)

Does the Composition of Gut Microbiota Affect Hypertension? Molecular Mechanisms Involved in Increasing Blood Pressure
por: Tokarek, Julita, et al.
Publicado: (2023)

The Influence of SARS-CoV-2 Infection on Lipid Metabolism—The Potential Use of Lipid-Lowering Agents in COVID-19 Management
por: Kowalska, Klaudia, et al.
Publicado: (2022)

New Insights into the Use of Empagliflozin—A Comprehensive Review
por: Forycka, Joanna, et al.
Publicado: (2022)

Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes
por: Tokarek, Julita, et al.
Publicado: (2023)

Molecular Interactions of Arterial Hypertension in Its Target Organs
por: Kućmierz, Joanna, et al.
Publicado: (2021)

Empagliflozin—A New Chance for Patients with Chronic Heart Failure
por: Kowalska, Klaudia, et al.
Publicado: (2021)

New Insights into Molecular Mechanisms of Chronic Kidney Disease
por: Frąk, Weronika, et al.
Publicado: (2022)

Advances in the Pathogenesis and Treatment of Resistant Hypertension
por: Dybiec, Jill, et al.
Publicado: (2023)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Acute Kidney Injury in COVID-19
por: Głowacka, Marta, et al.
Publicado: (2021)

Arterial Hypertension—Oxidative Stress and Inflammation
por: Krzemińska, Julia, et al.
Publicado: (2022)

Rhabdomyolysis-Induced AKI (RIAKI) Including the Role of COVID-19
por: Młynarska, Ewelina, et al.
Publicado: (2022)

The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes
por: Wronka, Magdalena, et al.
Publicado: (2022)

Chronic Kidney Disease as a Comorbidity in Heart Failure
por: Szlagor, Magdalena, et al.
Publicado: (2023)

Structural and Functional Changes in Aging Kidneys
por: Dybiec, Jill, et al.
Publicado: (2022)

New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
por: Wronka, Magdalena, et al.
Publicado: (2023)

New Insights into the Nephroprotective Potential of Lercanidipine
por: Hajdys, Joanna, et al.
Publicado: (2023)

Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease
por: Frąk, Weronika, et al.
Publicado: (2022)

Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab
por: Krzemińska, Julia, et al.
Publicado: (2022)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
por: Kowalska, Klaudia, et al.
Publicado: (2022)

Cellular Mechanisms of Coronary Artery Spasm
por: Franczyk, Beata, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Novel Insights into the Molecular Mechanisms of Atherosclerosis
por: Wojtasińska, Armanda, et al.
Publicado: (2023)

Advances in Treatment of Dyslipidemia
por: Dybiec, Jill, et al.
Publicado: (2023)

Statins in Chronic Kidney Disease—Effects on Atherosclerosis and Cellular Senescence
por: Fularski, Piotr, et al.
Publicado: (2023)

Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
por: Dąbek, Bartłomiej, et al.
Publicado: (2023)

The Impact of CKD on Uremic Toxins and Gut Microbiota
por: Rysz, Jacek, et al.
Publicado: (2021)

The Effect of Diet on the Survival of Patients with Chronic Kidney Disease
por: Rysz, Jacek, et al.
Publicado: (2017)

Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome
por: Rysz, Jacek, et al.
Publicado: (2017)

Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients
por: Gluba-Brzózka, Anna, et al.
Publicado: (2018)

Diabetes and Cardiovascular Risk in Renal Transplant Patients
por: Rysz, Jacek, et al.
Publicado: (2021)

Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma
por: Franczyk, Beata, et al.
Publicado: (2023)

The Impact of Aerobic Exercise on HDL Quantity and Quality: A Narrative Review
por: Franczyk, Beata, et al.
Publicado: (2023)

Gut-brain axis: altered microbiome and depression – review
por: Mohan, Anmol, et al.
Publicado: (2023)

Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson’s Disease
por: Kulcsarova, Kristina, et al.
Publicado: (2023)

The Brain-Gut-Microbiome Axis
por: Martin, Clair R., et al.
Publicado: (2018)

Pharmacogenomics of Hypertension Treatment
por: Rysz, Jacek, et al.
Publicado: (2020)

The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease
por: Rysz, Jacek, et al.
Publicado: (2020)

Ageing, Age-Related Cardiovascular Risk and the Beneficial Role of Natural Components Intake
por: Rysz, Jacek, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p906bpphiptf1tg57t8h35sdl8